HomeDCPXF • OTCMKTS
add
Dancann Pharma A/S
Market news
Financials
Income Statement
Revenue
Net income
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.35M | -16.25% |
Operating expense | 1.72M | -96.44% |
Net income | -2.16M | 95.96% |
Net profit margin | -159.63 | 95.17% |
Earnings per share | — | — |
EBITDA | -1.58M | 96.69% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.47M | 72.93% |
Total assets | 15.06M | -13.41% |
Total liabilities | 1.49M | -81.10% |
Total equity | 13.57M | — |
Shares outstanding | 3.99M | — |
Price to book | 0.00 | — |
Return on assets | -33.87% | — |
Return on capital | -37.40% | — |
Cash Flow
Net change in cash
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -2.16M | 95.96% |
Cash from operations | 4.10M | 432.15% |
Cash from investing | 1.00K | 100.34% |
Cash from financing | -835.00K | -138.44% |
Net change in cash | 3.27M | 406.67% |
Free cash flow | -1.01M | 96.98% |
About
Founded
2018
Website
Employees
12
